Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. Among authors: cosgrove cm. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
How safe is rucaparib in ovarian cancer?
Cosgrove CM, O'Malley DM. Cosgrove CM, et al. Expert Opin Drug Saf. 2018 Dec;17(12):1249-1255. doi: 10.1080/14740338.2018.1550067. Epub 2018 Dec 11. Expert Opin Drug Saf. 2018. PMID: 30449210 Review.
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
duPont NC, Enserro D, Brady MF, Moxley K, Walker JL, Cosgrove C, Bixel K, Tewari KS, Thaker P, Wahner Hendrickson AE, Rubin S, Fujiwara K, Casey AC, Soper J, Burger RA, Monk BJ. duPont NC, et al. Gynecol Oncol. 2022 Feb;164(2):398-405. doi: 10.1016/j.ygyno.2021.11.013. Epub 2021 Nov 29. Gynecol Oncol. 2022. PMID: 34857397 Free PMC article. Clinical Trial.
Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
Backes FJ, Wei L, Chen M, Hill K, Dzwigalski K, Poi M, Phelps M, Salani R, Copeland LJ, Fowler JM, Cohn DE, Bixel K, Cosgrove C, Hays J, O'Malley D. Backes FJ, et al. Gynecol Oncol. 2021 Sep;162(3):619-625. doi: 10.1016/j.ygyno.2021.06.032. Epub 2021 Jul 14. Gynecol Oncol. 2021. PMID: 34272090 Clinical Trial.
Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
Levine MD, Wang H, Sriram B, Khan A, Senter L, McLaughlin EM, Bixel KL, Chambers LM, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Backes FJ. Levine MD, et al. Among authors: cosgrove cm. Gynecol Oncol. 2024 Mar;182:51-56. doi: 10.1016/j.ygyno.2023.12.008. Epub 2024 Jan 22. Gynecol Oncol. 2024. PMID: 38262238
Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumab.
Gillen J, Mills KA, Dvorak J, Zheng B, Thai T, Salani R, Cosgrove CM, Davidson B, Thaker PH, Moore KN. Gillen J, et al. Among authors: cosgrove cm. Gynecol Oncol Rep. 2019 Oct 5;30:100502. doi: 10.1016/j.gore.2019.100502. eCollection 2019 Nov. Gynecol Oncol Rep. 2019. PMID: 31720357 Free PMC article.
64 results